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Abstract  
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Introduction: The outcome of medical treatment in patients with Graves’ disease (GD) is 
generally difficult to predict. In this study, we examined the hypothesis that gender may affect 
the outcome of treatment with antithyroid drugs (ATDs).  
Material and methods: This is a retrospective multicentre study including 717 (514 female 
and 203 male) patients with the first episode of GD treated for at least 12 months. Patients 
were classified as relapse, poorly controlled (several episodes of hyperthyroidism followed by 
euthyroidism and rarely hypothyroidism, occurring after titration of ATDs), and remission.   
Results: During the mean follow-up time of 26.75 ± 21.25 months (between 1 and 120 
months), 269 (37.5%), 176 (24.5%), and 272 (37.9%) patients experienced a relapse, a poorly 
controlled disease, and remained in remission, respectively. During the follow-up time, 223 
(43.4%) of the female and only 49 (24%) of the male patients remained in remission. Relapse 
and poorly controlled disease (non-remitting GD) were more common in male compared to 
female patients with GD (hazard ratio 1.26, 95% CI: 1.03–1.53, p = 0.025). Graves’ disease in 
male patients tended to relapse earlier, and male patients tended to have larger goitre sizes at 
diagnosis as well. The smoking habit was also significantly more frequent in males compared 
to female patients with GD.  
Conclusion: Male patients with GD have a markedly higher frequency of relapse and poorly 
controlled disease, as compared to female patients. Larger goitre size and higher frequency of 
smoking may contribute to the higher frequency of relapse and poorly controlled disease in 
male patients. 
Key words: hyperthyroidism; Graves’ disease; antithyroid drugs; gender 
 
Introduction 
Graves’ disease (GD) is an autoimmune disorder and is the most common cause of 
hyperthyroidism in iodine-replete areas of the world, affecting women approximately 5–6 
times more frequently than men [1]. According to epidemiological studies, about 3% of 
women and 0.5% of men develop GD during their lifetime [1]. Antithyroid drugs (ATDs), 
including methimazole and propylthiouracil, radioactive iodine treatment (RAI), and total 
thyroidectomy are the treatment options currently used for the treatment of GD. Although 
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ATDs are the preferred treatment option, relapse is frequent and occurs in approximately 50% 
of patients after discontinuation of ATDs [2]. Moreover, among patients treated with ATDs, a 
substantial number may experience several episodes of hyperthyroidism followed by 
euthyroidism and rarely hypothyroidism or vice versa, ensuing after titration of ATDs [3]. On 
the other hand, RAI treatment and total thyroidectomy usually result in permanent 
hypothyroidism that necessitates life-long levothyroxine treatment [3]. Therefore, to achieve a 
euthyroid state during treatment and long-term remission after discontinuation of the ATDs, 
appropriate selection of patients for treatment with ATDs is important.   
Several factors including severe hyperthyroidism, large goitre size, persistent high 
thyrotropin receptor antibody (TRAb) levels, high anti-thyroid peroxidase (anti-TPO) 
antibody levels, the presence of orbitopathy, and smoking habit have been suggested as risk 
factors for relapse after discontinuation of ATDs [2, 3]. However, the results of the studies 
evaluating the association between gender and relapse of GD are generally conflicting. For 
instance, in a recent meta-analysis, male gender has not been found to be associated with 
relapse of GD after discontinuation of the ATDs, whereas in a study conducted by Allahbadia 
et al., after adjusting for the other confounding factors, relapse was significantly more 
common in male compared to female patients with GD, after discontinuation of the ATDs [4]. 
However, in studies assessing the association between gender and relapse of GD, the number 
of patients, particularly the number of male patients with GD, is generally low, and therefore 
the interpretation of the results is challenging. So, in this retrospective multicentre study, we 
examined the hypothesis that gender may affect the clinical response to treatment during ATD 
treatment, and relapse after discontinuation of the ATDs, in a large cohort of patients with 
GD, who were diagnosed, treated, and followed-up in six tertiary endocrinology referral 
centres.   
 
Material and methods 
Patients 
This study included 717 (514 female and 203 male) patients with the first episode of 
GD from January 2008 to January 2019, in six endocrinology referral centres across Turkey. 
Patients < 18 years old, pregnant patients, with ATD treatment < 12 months, patients with a 
history of prior RAI treatment or thyroidectomy, and patients with major side effects of ATDs 
were not included in the study. Methimazole as a titration regimen was started in all patients, 
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with an initial dose of 10-30 mg/day, and the ATD titration to the lowest dose (generally 2.5–
5 mg/day) was performed according to the follow-up free thyroxine (fT4) and free 
triiodothyronine (fT3) levels. However, patients with minor side effects of methimazole were 
switched to appropriate doses of propylthiouracil. All patients were classified as relapse, 
poorly controlled, or remission. The clinical and biochemical evaluation of the patients was 
performed at the initial visit before the start of ATDs, monthly until the restoration of thyroid 
functions, subsequently at three-month intervals during ATD treatment and dose titration, and 
at 3-6-month intervals after discontinuation of the ATDs.  
Graves’ disease, poorly controlled disease, and relapse were defined as previously reported 
[3]. In brief, GD was defined as clinical hyperthyroidism with or without extrathyroidal 
manifestations associated with suppressed or undetectable serum of thyroid-stimulating 
hormone (TSH), elevated serum fT4 and/or fT3 levels, diffuse hypoechoic ultrasonographic 
appearance of the thyroid gland, high TRAb titres, or high uptake of 99m-Tc pertechnetate in 
association with clinical and biochemical findings in patients with TRAb levels within the 
normal reference ranges. The poorly controlled disease was defined as several episodes of 
hyperthyroidism followed by euthyroidism and rarely hypothyroidism or vice versa, occurring 
after titration of ATDs, during at least 12 months of follow-up, in a self-reported medication 
adherent patient [3]. Relapse was defined as overt clinical and biochemical hyperthyroidism 
in a euthyroid patient, after discontinuation of the lowest dose of ATDs. The follow-up time 
in patients with relapse and remission was recorded from the first day after the 
discontinuation of the ATDs, and the beginning of the ATD treatment in patients with the 
poorly controlled disease, because treatment with ATDs was difficult to discontinue, even for 
several years in some of these patients. The study protocol was approved by the Local Ethics 
Committee.  
Clinical and laboratory data 
Clinical and laboratory data were obtained through the computer records of each centre. The 
following data of the patients at the first episode of GD were recorded: gender, age, serum 
TSH, fT3, fT4, TRAb, anti-TPO and anti-thyroglobulin (anti-TG) antibody levels, goitre size 
according to the WHO classification (0–III), smoking status, the presence of orbitopathy, the 
type of ATD used, date of start and discontinuation of ATDs, treatment duration, time of 
relapse, and application of definitive treatment, if any. Orbitopathy was classified according 
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to Werner’s criteria as absent (class 0–1) or present (class 2–6: the presence of inflammatory 
signs, proptosis, extraocular muscle, and corneal involvement) [5].   
Laboratory analysis to assess serum TSH, fT3, fT4, TRAb, anti-TPO, and anti-TG 
levels was performed during the first presentation of the patients in each study centre. Serum 
TSH, FT3, fT4, anti-TPO, and anti-TG levels were assessed by direct chemiluminescence 
immunoassay method in all centres (Cobas Elecsys, Roche Diagnostics, Manheim, Germany, 
and Siemens, ADVIA Centaur XP Immunoassay System, Tarrytown NY). Serum TRAb 
levels were assessed by chemiluminescence immunoassay, TRAb-Fast ELISA, 
radioimmunoassay, and radioreceptor assay methods (Cobas Elecsys, Roche Diagnostics, 
Manheim, Germany, Euroimmun AG Seekamp, Lübeck, Germany; anti-rTSH, RIA kits, 
Immunotech, Beckman Coulter, Prague, Czech Republic; and TRAK Dyno human, 
BRAHMS Germany) in different study centres. The normal laboratory reference values for 
TRAb, as were established by the manufacturers, were < 1.5 IU/L for the first two assay 
methods, < 1.75 IU/L for the third assay method, and qualitatively as negative and positive in 
the last assay method.  
Statistical analysis 
  The statistical analysis was performed using PASW Statistics 18 for Windows 
statistical software package (IBM Corp., Armonk, NY).  The two-sample Wilcoxon rank-sum 
(Mann-Whitney) or Kruskal-Wallis tests were used for variables not fitting a normal (or 
parametric) distribution. In contingency tables for categorical variables, the Fisher or chi-
squared tests were used. Cox proportional hazards regression models were used to estimate 
the association of gender and the other predetermined risk factor with the outcome of ATD 
treatment. In regression analysis, we used the same cut-off values for age, TRAb, goitre size, 
and fT4, which were previously determined by Vos et al. [6]. The Kaplan-Meier method was 
used to demonstrate the cumulative rate of remission according to gender during the first two 
years of follow-up. Missing data were not imputed and were left as lost. All hypothesis tests 
were two-sided, with a significance level of 0.05.  
 
 
Results 
In the present study, during the mean follow-up time of 26.75 ± 21.25 months 
(between 1–120 months) after ATD withdrawal, 269 (37.5%), 176 (24.5%), and 272 (37.9%) 
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patients experienced a relapse, had a poorly controlled disease, and remained in remission, 
respectively. Relapse and poorly controlled disease were ensued in 185 (36%) and 106 
(20.6%) of the females and 84 (41.4%) and 70 (34.5%) of the male patients, respectively (p = 
0.001, χ2 test). During the follow-up period, 223 (43.4%) of the females and only 49 (24%) of 
the males remained in remission (p < 0.001, χ2 test). The time to relapse after discontinuation 
of the ATDs was also significantly different between both genders. Among female patients, 
28.2, 24.1, 38.8, and 16.9% experienced a relapse during the first six months, between 7–12 
months, between 13–24 months, and > 24 months after discontinuation of the ATDs, 
respectively, whereas among male patients, 49.5, 24.2, 14.7, and 11.6% experienced a relapse 
in the same time periods, after discontinuation of the ATDs, respectively (p = 0.001, χ2 test). 
As shown in Table 1, male patients with GD also tended to have larger goitre size at 
presentation, as compared to female patients (p = 0.023). Other variables including TSH, fT3, 
fT4, TRAb, anti-TPO, and anti-TG antibodies were not different between male and female 
patients (Tab. 1). Due to the quite similar clinical and biochemical features at presentation, 
the patients with relapse and the poorly controlled disease were combined in a single group as 
a non-remitting group in uni- and multivariate analysis. In univariate analysis, male gender, 
age < 40 years, TRAb levels between 6–20 IU/mL, and goitre sizes II and III were 
significantly associated with the non-remitting GD (Tab. 2). However, although the effect of 
each parameter became smaller in multivariate analysis, male gender remained independently 
associated with non-remitting GD (Tab. 2). The cumulative rate of relapse according to the 
gender after discontinuation of the ATDs is shown in the Kaplan-Meier curve in Fig 1.  
 
Discussion 
In the present study, we evaluated the effect of gender on response to ATDs and the 
risk of relapse after discontinuation of ATDs. According to the results obtained from our 
study, male patients had a markedly worse outcome during and after ATD treatment, with a 
remission rate of only 24% compared with 43.4% for females. 
An ideal treatment goal of GD would include the prompt control of the disease 
manifestations, restoration, and maintenance of the euthyroid state, minimal morbidity due to 
the disease itself, or adverse events resulting from treatment, as well as a reasonable cost [7]. 
Considering these treatment goals, treatment with ATDs is a reasonable treatment option in 
patients with GD. However, the relapse rate is high and occurs in 30-60% of cases after 
discontinuation of the ATDs [8]. On the other hand, although rare, ATDs are associated with 
some serious adverse reactions that could be life-threatening [9, 10]. Therefore, the prediction 
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of response to ATDs and risk factors for relapse before the start of ATDs are quite important. 
Several individual, as well as combined, risk factors have been suggested to predict the risk of 
relapse in patients with GD [2, 6–8, 11, 12], but the results are far from ideal. Considering 
that females are more likely to develop autoimmune thyroid disease, including GD, compared 
to males [13] but males with GD may have more severe extrathyroidal manifestations, it has 
been suggested that males may be less responsive to ATDs and have a higher relapse rate 
[14]. However, as the results of the studies are conflicting and the level of evidence is low, the 
2016 American Thyroid Association guidelines on diagnosis and management of 
hyperthyroidism state that there may be a higher likelihood of relapse after discontinuation of 
ATDs in males with GD, but do not make a definite recommendation on the choice of 
treatment between two genders [15]. Allahabdia et al. were among the first to assess the 
frequency of relapse between female and male patients with GD in the UK [4]. They found a 
higher rate of relapse in male compared to female patients with GD, after adjusting for 
possible confounders (OR = 2.80; 95% CI: 1.31–5.98). They concluded that male patients 
with GD should be offered definitive treatment with radioiodine or surgery soon after 
presentation. However, in that study, TRAb levels at presentation, a potential risk factor for 
relapse after discontinuation of the ATDs, were not assessed. Our study results are in line 
with those reported by Allahabadia et al. In our study, 62% of the patients had non-remitting 
GD. Males, however, had a markedly worse outcome during and after ATD treatment, with a 
non-remitting GD rate of 76% compared with 56.6% for females (p = 0.001). As 
demonstrated in Table 2, after adjusting for the well-known risk factors of relapse, male 
gender was independently associated with the risk of non-remitting disease (hazard ratio [HR] 
= 1.26, 95% confidence interval [CI]: 1.03–1.53, p = 0.025). Furthermore, relapse during the 
first six months after discontinuation of the ATDs was more likely to occur in male patients 
with GD as compared to females. However, in a recent study carried-out by Diker-Cohen et 
al. in Israel, the relapse rate after discontinuation of the ATDs was not different between male 
and female patients with GD [16]. Nevertheless, in that study, other well-known risk factors 
for relapse, including younger age, fT4, and TRAb, were not associated with relapse of GD. 
The lack of association between these well-known risk factors and relapse in their study may 
be attributed to the high prevalence of iodine deficiency in Israel [17]; therefore, the results of 
their study may not apply to iodine-sufficient areas. In a recent meta-analysis, orbitopathy, 
smoking, larger goitre size and thyroid volume, fT4, fT3, and TRAb levels were significantly 
associated with relapse while gender and age did not show any association with relapse [2]. 
Recently, Magri et al. assessed the influence of gender on the outcome of treatment with 
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ATDs in 294 patients with GD in Italy [18]. In that study, relapse after discontinuation of the 
ATDs was significantly more frequent in male compared to female patients with GD (59.1% 
vs. 36.0%, p = 0.003). Although TRAb, fT3, and fT4 levels were not different between both 
genders, thyroid volume assessed by sonography was greater in males, and the frequency of 
autoimmune disease was more common among the relatives of males compared to females. 
They concluded that a larger goitre size and a strong genetic autoimmune background may 
explain the higher frequency of relapse in male patients with GD [18]. Our study results are in 
line with those reported by Magri et al. While the severity of hyperthyroidism at first 
diagnosis, as assessed by fT3 and fT4 levels, was not different between male and female 
patients, the goitre size assessed by manual palpation was significantly lager in male patients 
(Tab. 1).  
The association between relapse of GD and goitre size has been demonstrated in 
several studies [2, 3, 6], but the reason for the larger goitre size in male compared to female 
patients with GD is not clear so far and should be investigated in further studies. Although the 
goitre size in healthy euthyroid males is larger than females due to the higher body weight 
[19], as shown in Table 1, grade II and III goitre were also present in 46% of the females in 
our study. We think that moderate iodine insufficiency in our country may have contributed to 
the larger goitre sizes detected in our study participants [20]. Another factor that may have 
contributed to a higher frequency of relapse in male patients in our study is the higher 
frequency of smoking habit among males. Studies have shown a significantly higher 
frequency of relapse of GD in tobacco smokers, particularly in male patients [2, 21]. 
Although statistically it did not reach significance, smoking habit was also more frequent 
among male patients in the study of Magri et al. (42.5% vs. 32.5%) [18].  
One of the main differences between our study and the studies cited above [4, 16, 18] 
is that we included a subgroup of patients with poorly controlled disease. These patients share 
similar clinical and biochemical features with patients who experience relapse [3]. As 
demonstrated in Table 1, the poorly controlled disease was also more frequent in male 
compared to female patients (p < 0.001). This result suggests that male gender is also 
associated with a higher frequency of poorly controlled disease as well as relapse. Therefore, 
the gender of the patient should be taken into account when considering treatment for GD.  
  Our study has several limitations. The first, main limitation is the retrospective design, 
which makes our study subject to reporting bias. Second, TRAb levels were assessed in 117 
patients by qualitative method; therefore, the TRAb levels of these patients could not be 
included in uni- and multivariate analysis, as well as in between groups analysis. Third, 
 8 
orbitopathy was not recorded according to the severity and activity as recommended by the 
recently published guidelines [22]. Fourth, goitre size was only assessed by manual palpation 
rather than thyroid ultrasonography. On the other hand, the strength of our study derives from 
the inclusion of a large number of patients, particularly the large number of male patients with 
GD, with relatively long-term follow-up data.  
 
Conclusions 
 According to the present study results, relapse and poorly controlled disease during 
treatment with ATDs were significantly more common in male compared to female patients 
with GD. GD in male patients tended to relapse earlier compared to females. The higher 
frequency of relapse and poorly controlled disease in male patients might be attributed to the 
larger goitre size as well as a higher frequency of smoking in male patients. Nevertheless, the 
exact cause and whether the genetic background of male patients plays a role in the higher 
frequency of relapse as well as a poorly controlled disease should be determined in further 
studies. However, along with other well-known risk factors for relapse, the gender of the 
patients should be taken into consideration when deciding treatment for GD. 
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Table 1. Clinical and biochemical characteristics of 717 patients with the first episode of 
Graves’ disease (GD), as the whole group, and according to the gender of the patients 
Parameter All patients Female Male  p value 
 10 
717 (100%) 514 (71.7%)  203 (28.3%) 
Age at diagnosis 
(years) 
 
< 40 
≥ 40 
42.27 ± 13.6 
 
353 (49.2)  
364 (50.8)  
41.6 ± 13.68 
 
263 (51) 
251 (49)  
43.9 ± 13.31 
 
90 (44.3) 
113 (55.7) 
 
Goitre size 
Grade 0 (%) 
Grade I (%) 
Grade II (%) 
Grade III (%) 
 
44 (6.1)  
319 (44.5) 
274 (38.2) 
80 (11.2) 
 
32 (6.2) 
246 (47.9)  
185 (36) 
51 (9.9) 
 
12 (5.9) 
73 (36) 
89 (43.8) 
29 (14.3) 
 
TRAb [IU/L]* 11.96 ± 11.74 11.08 ± 11.32   12.21 ± 12.13 0.44 
FT4 [pmol/L] 44.46 ± 22.09 43.74 ± 21.61 46.28 ± 23.21 0.23 
FT3 [pg/mL] 10.95 ± 6.68 10.86 ± 6.58  11.17 ± 6.97   0.70 
TSH [IU/L] 0.009 ± 0.012  0.009 ± 0.013   0.007 ± 0.007 0.62 
Anti-TPO 
[U/L]
     
0.08 
 
254 ± 289 36.7 ± 282.1 298 ± 303 0.08 
Anti-TG [U/L] 336 ± 685.4 330 ± 643 352.2 ± 785.6 0.67 
Smoking status 
(yes/no)  
284 (39.6)/433 
(60.4) 
169 (32.9)/335 
(65.2) 
115 (56.7)/87 
(42.9) 
< 0.001 
Orbitopathy (yes/no) 203 (28.3)/514 
(71.7)   
133 (25.9)/380 
(73.9) 
70 (34.5)/132 (65) 0.053 
Treatment 
duration* 
22.27 ± 11.8 22.08 ± 11.1 22.77 ± 13.5 0.88 
Follow-up duration* 26.75 ± 21.25 27.74 ± 20.7  24.25 ± 22.48 0.005 
Treatment outcome 
Remission (%) 
Relapse  
Poorly controlled 
disease 
 
272 (37.9) 
269 (37.6) 
176 (24.5) 
445 (62.1) 
 
223 (43.4) 
185 (36) 
106 (20.6) 
291 (56.6) 
 
49 (24.1) 
84 (41.4) 
70 (34.5) 
154 (75.9) 
 
 
< 0.001 
 11 
Non-remitting 
disease† 
Final treatment 
ATD (%) 
RAI treatment (%) 
Total thyroidectomy 
(%)  
 
167 (23.3) 
129 (18) 
149 (20.8) 
 
121 (23.5) 
72 (14)  
98 (19) 
 
46 (22.6) 
57 (28) 
51 (25) 
 
TRAb — thyrotropin receptor antibody; fT4 — free thyroxine; fT3 — free triiodothyronine; TSH — 
thyroid-stimulating control; anti-TPO — anti-thyroid peroxidase; anti-TG — anti-thyroglobulin; ATD 
— antithyroid drugs; RAI — radioactive iodine, *months, †relapse + poorly controlled disease 
The smoking status of 11 patients was unknown. The orbitopathy status of 2 patients was unknown. 
The Anti-TPO antibody levels were not available for 102 patients. The anti-TG antibody levels were 
not available for 123 patients. TRAb levels were assessed qualitatively as positive and negative results 
in 117 patients (84 female and 33 male) and were not included in between-group analysis  
 
Table 2. The risk of relapse and poorly controlled disease (non-remitting disease) according 
to gender, age, TRAb level, and goitre size determined by uni- and multivariate analysis 
Variable HR (95% CI)* p value HR (95% 
CI)** 
p value 
Gender 
Female 
Male 
 
Ref 
1.48 (1.21–
1.81) 
 
 
< 0.001  
 
Ref 
1.26 (1.03–
1.53)  
 
 
0.025 
Age  
≥ 40  
< 40 
 
Ref 
1.40 (1.16–1.7) 
 
 
< 0.001 
 
Ref 
1.3 (1.08–1.43) 
 
 
0.014 
Goitre size 
0–I 
II–III 
 
Ref 
3.2 (2.61–3.95) 
 
 
< 0.001 
 
Ref 
2.7 (2.12–3.41)  
 
 
< 0.001 
TRAb [IU/L]†  
< 6  
6–19.9 
> 19.9 
 
Ref 
2.04 (1.56–
4.23) 
1.16 (1.10–
1.49) 
 
 
< 0.001 
0.24 
 
Ref 
1.28 (1.05–
1.69) 
1.01 (0.78–
1.31) 
 
 
0.036 
0.89 
 12 
fT4 [pmol/L]  
< 40 
≥ 40 
 
Ref 
1.14 (0.76–
1.36) 
 
 
0.24 
 
Ref 
0.82 (0.62–
1.19) 
 
 
0.48 
TRAb — thyrotropin receptor antibody; fT4 — free thyroxine; HR — hazard ratio; CI — confidence 
interval; *univariate analysis; **multivariate analysis; †quantitative TRAb levels were available for 
600 patients 
 
Figure 1. The cumulative rate of relapse according to gender after discontinuation of 
antithyroid drugs (ATDs), shown in a Kaplan-Meier curve  
 
 
